| Trial ID: | L3727 |
| Source ID: | NCT05459701
|
| Associated Drug: |
Dapagliflozin 10mg Tab
|
| Title: |
Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Nonalcoholic Fatty Liver Disease|Type 2 Diabetes
|
| Interventions: |
DRUG: Dapagliflozin 10mg Tab|OTHER: Placebo
|
| Outcome Measures: |
Primary: leptin (ng/ml), leptin by enzyme-linked immunosorbent assay (ELISA)., 6 months|adiponectin (pg/ml), adiponectin by enzyme-linked immunosorbent assay (ELISA)., 6 months|VCAM-1 (ng/ml), VCAM-1 was analyzed in serum using the human VCAM-1 ELISA kits., 6 months |
|
| Sponsor/Collaborators: |
Sponsor: Rehab Werida | Collaborators: University of Alexandria
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-05-01
|
| Completion Date: |
2024-07-31
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-04
|
| Locations: |
Rehab Hussein Werida, Damanhūr, Elbehairah, 31527, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05459701
|
